You are here

  • Home
  • Archive
  • Volume 15, Issue 4
  • Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

Article metrics

Article menu
Download PDFPDF
ORIGINAL ARTICLE
Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

 

Online download statistics by month:

Online download statistics by month: March 2019 to May 2023

AbstractFullPdf
Mar 20191400
Apr 20191200
May 20192101
Jun 2019801
Jul 2019901
Aug 2019700
Sep 20191000
Oct 2019400
Nov 2019600
Dec 20192200
Jan 20201700
Feb 20201000
Mar 20201401
Apr 2020200
May 20201300
Jun 20201100
Jul 2020800
Aug 20202200
Sep 20201300
Oct 20205200
Nov 2020800
Dec 2020800
Jan 20211500
Feb 2021200
Mar 2021303
Apr 2021400
Jul 2021200
Sep 2021200
Oct 20211001
Nov 2021601
Dec 2021900
Jan 20221400
Feb 20221800
Mar 20221401
Apr 20221700
May 20223000
Jun 20223600
Jul 20221700
Aug 20223500
Sep 20222600
Oct 20224600
Nov 20221803
Dec 20222100
Jan 2023201
Feb 20234600
Mar 20231400
Apr 20231000
May 2023200
Total710014